IN8bio, Inc. (INAB)
1.05
+0.06
(+6.50%)
USD |
NASDAQ |
Oct 23, 16:00
1.04
-0.01
(-0.95%)
After-Hours: 20:00
IN8bio Enterprise Value : -5.433M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -5.433M |
| October 22, 2026 | -6.065M |
| October 21, 2026 | -5.039M |
| October 20, 2026 | -4.546M |
| October 19, 2026 | -5.039M |
| October 16, 2026 | -4.842M |
| October 15, 2026 | -4.103M |
| October 14, 2026 | -3.955M |
| October 13, 2026 | -4.152M |
| October 12, 2026 | -3.660M |
| October 09, 2026 | -2.576M |
| October 08, 2026 | -2.182M |
| October 07, 2026 | -1.985M |
| October 06, 2026 | -2.083M |
| October 05, 2026 | -1.788M |
| October 02, 2026 | -1.985M |
| October 01, 2026 | -1.985M |
| September 30, 2026 | -2.674M |
| September 29, 2026 | -3.019M |
| September 28, 2026 | -3.561M |
| September 25, 2026 | -3.955M |
| September 24, 2026 | -4.054M |
| September 23, 2026 | -4.941M |
| September 22, 2026 | -4.546M |
| September 21, 2026 | -5.335M |
| Date | Value |
|---|---|
| September 18, 2026 | -5.138M |
| September 17, 2026 | -5.236M |
| September 16, 2026 | -5.827M |
| September 15, 2026 | -5.433M |
| September 14, 2026 | -4.842M |
| September 11, 2026 | -5.236M |
| September 10, 2026 | -4.941M |
| September 09, 2026 | -5.138M |
| September 08, 2026 | -4.546M |
| September 04, 2026 | -3.955M |
| September 03, 2026 | -4.349M |
| September 02, 2026 | -4.941M |
| September 01, 2026 | -5.039M |
| August 31, 2026 | -4.941M |
| August 28, 2026 | -5.581M |
| August 27, 2026 | -5.532M |
| August 26, 2026 | -4.103M |
| August 25, 2026 | -4.251M |
| August 24, 2026 | -4.152M |
| August 21, 2026 | -3.167M |
| August 20, 2026 | -3.857M |
| August 19, 2026 | -3.955M |
| August 18, 2026 | -4.546M |
| August 17, 2026 | -4.842M |
| August 14, 2026 | -4.941M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.781M |
| Total Expenses (Quarterly) | 4.781M |
| EPS Diluted (Quarterly) | -0.2456 |
| Earnings Yield | -177.4% |
| Normalized Earnings Yield | -177.37 |